Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke

医学 冲程(发动机) 轻微中风 心脏病学 内科学 急性中风 缺血性中风 组织纤溶酶原激活剂 缺血 机械工程 狭窄 工程类
作者
Dawei Chen,Yu Cui,Zhong-He Zhou,Hong Zhang,Lixia Wang,Weizhong Wang,Liying Shen,Liyan Guo,Er-Qiang Wang,Ruixian Wang,Jing Han,Yu-Ling Dong,Jing Li,Yongzhong Lin,Qingcheng Yang,Li Zhang,Jingyu Li,Jin Wang,Lei Xia,Guang-Bin Ma
出处
期刊:JAMA [American Medical Association]
卷期号:329 (24): 2135-2135 被引量:242
标识
DOI:10.1001/jama.2023.7827
摘要

Importance: Intravenous thrombolysis is increasingly used in patients with minor stroke, but its benefit in patients with minor nondisabling stroke is unknown. Objective: To investigate whether dual antiplatelet therapy (DAPT) is noninferior to intravenous thrombolysis among patients with minor nondisabling acute ischemic stroke. Design, Setting, and Participants: This multicenter, open-label, blinded end point, noninferiority randomized clinical trial included 760 patients with acute minor nondisabling stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤5, with ≤1 point on the NIHSS in several key single-item scores; scale range, 0-42). The trial was conducted at 38 hospitals in China from October 2018 through April 2022. The final follow-up was on July 18, 2022. Interventions: Eligible patients were randomized within 4.5 hours of symptom onset to the DAPT group (n = 393), who received 300 mg of clopidogrel on the first day followed by 75 mg daily for 12 (±2) days, 100 mg of aspirin on the first day followed by 100 mg daily for 12 (±2) days, and guideline-based antiplatelet treatment until 90 days, or the alteplase group (n = 367), who received intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg) followed by guideline-based antiplatelet treatment beginning 24 hours after receipt of alteplase. Main Outcomes and Measures: The primary end point was excellent functional outcome, defined as a modified Rankin Scale score of 0 or 1 (range, 0-6), at 90 days. The noninferiority of DAPT to alteplase was defined on the basis of a lower boundary of the 1-sided 97.5% CI of the risk difference greater than or equal to -4.5% (noninferiority margin) based on a full analysis set, which included all randomized participants with at least 1 efficacy evaluation, regardless of treatment group. The 90-day end points were assessed in a blinded manner. A safety end point was symptomatic intracerebral hemorrhage up to 90 days. Results: Among 760 eligible randomized patients (median [IQR] age, 64 [57-71] years; 223 [31.0%] women; median [IQR] NIHSS score, 2 [1-3]), 719 (94.6%) completed the trial. At 90 days, 93.8% of patients (346/369) in the DAPT group and 91.4% (320/350) in the alteplase group had an excellent functional outcome (risk difference, 2.3% [95% CI, -1.5% to 6.2%]; crude relative risk, 1.38 [95% CI, 0.81-2.32]). The unadjusted lower limit of the 1-sided 97.5% CI was -1.5%, which is larger than the -4.5% noninferiority margin (P for noninferiority <.001). Symptomatic intracerebral hemorrhage at 90 days occurred in 1 of 371 participants (0.3%) in the DAPT group and 3 of 351 (0.9%) in the alteplase group. Conclusions and Relevance: Among patients with minor nondisabling acute ischemic stroke presenting within 4.5 hours of symptom onset, DAPT was noninferior to intravenous alteplase with regard to excellent functional outcome at 90 days. Trial Registration: ClinicalTrials.gov Identifier: NCT03661411.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
树123发布了新的文献求助10
1秒前
会飞的鹦鹉完成签到,获得积分10
2秒前
2秒前
热心的咖啡豆完成签到 ,获得积分10
4秒前
UHPC完成签到,获得积分10
5秒前
十四行诗发布了新的文献求助10
5秒前
科研通AI2S的应助被vividtry采纳,获得10
5秒前
搜集达人的应助被楠小楠采纳,获得10
5秒前
小蘑菇的应助被楠小楠采纳,获得10
5秒前
烟花的应助被楠小楠采纳,获得10
6秒前
香蕉觅云的应助被SHNU_YS采纳,获得10
6秒前
6秒前
李健的小迷弟的应助被楠小楠采纳,获得10
6秒前
6秒前
zs发布了新的文献求助30
6秒前
不放弃完成签到,获得积分10
6秒前
今后的应助被马浩然采纳,获得10
6秒前
HYYY发布了新的文献求助20
7秒前
单薄幻梦发布了新的文献求助10
7秒前
8秒前
sunny完成签到,获得积分10
8秒前
丘比特的应助被September采纳,获得10
9秒前
青枣不甜完成签到,获得积分10
10秒前
cdercder的应助被fsdgsd采纳,获得10
10秒前
所所的应助被学阿斗采纳,获得10
11秒前
YXM发布了新的文献求助10
11秒前
纯真大象发布了新的文献求助10
11秒前
11秒前
maT发布了新的文献求助10
11秒前
szztty发布了新的文献求助10
12秒前
小马甲的应助被kuku采纳,获得10
12秒前
sunny完成签到,获得积分10
13秒前
qin202569发布了新的文献求助10
13秒前
繁荣的瑛的应助被楠小楠采纳,获得10
14秒前
初景的应助被楠小楠采纳,获得20
14秒前
科研通AI2S的应助被楠小楠采纳,获得10
14秒前
科研通AI6.4的应助被楠小楠采纳,获得10
14秒前
余香的应助被楠小楠采纳,获得10
14秒前
orixero的应助被细心又菡采纳,获得10
14秒前
DW的应助被楠小楠采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178960
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805682
捐赠科研通 7774071
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640